Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BMRN

Biomarin Pharmaceutical Inc

Oct 28 • 04:00PM ET

53.49

+0.82 1.56 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: VTI IJH VB VBK VXF XBI MDY IBB IJJ SPMD

Scroll to Statements

Index	-	P/E	20.04	EPS (ttm)	2.67	Insider Own	1.49%	Shs Outstand	192.10M	Perf Week	-0.59%
Market Cap	10.27B	Forward P/E	11.85	EPS next Y	4.51	Insider Trans	-0.07%	Shs Float	189.15M	Perf Month	-0.98%
Enterprise Value	9.39B	PEG	0.60	EPS next Q	0.80	Inst Own	98.56%	Short Float	4.50%	Perf Quarter	-9.05%
Income	520.42M	P/S	3.34	EPS this Y	26.55%	Inst Trans	-2.18%	Short Ratio	3.61	Perf Half Y	-15.47%
Sales	3.07B	P/B	1.70	EPS next Y	61.35%	ROA	7.20%	Short Interest	8.51M	Perf YTD	-18.62%
Book/sh	31.53	P/C	6.95	EPS next 5Y	33.33%	ROE	9.07%	52W High	73.51 -27.23%	Perf Year	-24.01%
Cash/sh	7.70	P/FCF	12.34	EPS past 3/5Y	- -	ROIC	7.82%	52W Low	51.56 3.73%	Perf 3Y	-40.57%
Dividend Est.	-	EV/EBITDA	13.29	Sales past 3/5Y	15.43% 10.98%	Gross Margin	82.82%	Volatility	4.00% 2.91%	Perf 5Y	-30.98%
Dividend TTM	-	EV/Sales	3.05	EPS Y/Y TTM	60.21%	Oper. Margin	20.29%	ATR (14)	1.69	Perf 10Y	-50.14%
Dividend Ex-Date	-	Quick Ratio	3.10	Sales Y/Y TTM	11.92%	Profit Margin	16.93%	RSI (14)	46.94	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	4.83	EPS Q/Q	-129.25%	SMA20	-0.64%	Beta	0.33	Target Price	91.21
Payout	0.00%	Debt/Eq	0.10	Sales Q/Q	4.55%	SMA50	-2.92%	Rel Volume	2.79	Prev Close	52.67
Employees	3040	LT Debt/Eq	0.10	Earnings	Oct 27 AMC	SMA200	-11.00%	Avg Volume	2.36M	Price	53.49
IPO	Jul 23, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	39.65% -0.08%	Trades		Volume	6,452,951	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-25	Initiated	H.C. Wainwright	Neutral	$60
Sep-03-25	Initiated	Raymond James	Outperform	$85
Jul-03-25	Resumed	Morgan Stanley	Overweight	$97
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116

Show Previous Ratings

Oct-28-25 04:59PM	Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday (Motley Fool)
02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
12:24PM	Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy? (Insider Monkey)
12:10PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today (StockStory)
01:31AM	BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook (StockStory)
11:00PM	Loading…
Oct-27-25 11:00PM	BioMarin Pharmaceutical Inc (BMRN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
06:00PM	Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics (Zacks)
05:30PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates (Zacks)
04:32PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates (StockStory)
04:03PM	BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update (PR Newswire)
01:55PM	BioMarin, following sluggish sales, to offload hemophilia gene therapy (BioPharma Dive)
Oct-25-25 11:03PM	BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 12:43AM	3 of Wall Street's Favorite Stocks to Target This Week (StockStory)
Oct-23-25 10:00AM	Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? (Zacks)
04:05PM	Loading…
Oct-22-25 04:05PM	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET (PR Newswire)
Oct-17-25 09:54PM	Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Oct-08-25 12:57AM	Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? (Insider Monkey)
Oct-06-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Oct-02-25 09:46AM	Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors (Insider Monkey)
Oct-01-25 08:08PM	BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-30-25 04:01AM	Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT (Insider Monkey)
Sep-19-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Sep-18-25 12:39PM	BioMarin Pharmaceutical Inc.'s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials (Insider Monkey)
Sep-17-25 02:27PM	BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Sep-16-25 12:37PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
09:51AM	New Study Results Highlight BioMarin's VOXZOGO Efficacy in Children (Insider Monkey)
Sep-15-25 11:31PM	Reflecting On Therapeutics Stocks' Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) (StockStory)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
03:11PM	Loading…
Sep-09-25 03:11PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Sep-08-25 02:39PM	Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock? (Zacks)
11:46AM	Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today (StockStory)
09:49AM	Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls (The Fly)
09:00AM	BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting (PR Newswire)
04:00AM	Inside pharmas race to deliver new treatments for dwarfism (Pharma Voice)
04:00AM	Can drug developers help kids with dwarfism reach new heights? (Pharma Voice)
Sep-06-25 11:05AM	BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism (PR Newswire)
Sep-03-25 11:30AM	BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-01-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Aug-31-25 12:10AM	What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? (Insider Monkey)
Aug-28-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Aug-27-25 09:00AM	BioMarin to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-25 11:29AM	Bernstein Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Aug-22-25 11:57PM	Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86 (Insider Monkey)
Aug-20-25 12:02AM	2 Reasons to Watch BMRN and 1 to Stay Cautious (StockStory)
Aug-19-25 12:08AM	Predicting the Next Rule Breaker Buyout (Motley Fool)
Aug-18-25 09:50AM	BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Aug-13-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Aug-12-25 11:53PM	The Top 5 Analyst Questions From BioMarin Pharmaceutical's Q2 Earnings Call (StockStory)
11:41PM	BMRN Q2 Deep Dive: Pipeline Advances and Strategic Expansion Drive Upbeat Results (StockStory)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
09:10AM	Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 (Insider Monkey)
Aug-08-25 03:42AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Aug-07-25 12:44AM	1 Healthcare Stock on Our Watchlist and 2 We Find Risky (StockStory)
Aug-06-25 07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
Aug-05-25 10:17AM	BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View (Zacks)
03:02AM	BioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-04-25 06:00PM	BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:20PM	BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:47PM	BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars (StockStory)
04:20PM	BioMarin: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS (PR Newswire)
Aug-03-25 02:00PM	Palantir, Advanced Micro, Walt Disney, Pfizer, ZoomInfo, and More Stocks to Watch This Week (Barrons.com)
Aug-02-25 11:04PM	BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jul-28-25 10:00AM	BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
02:07AM	Leerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT (Insider Monkey)
Jul-23-25 01:18PM	Will Escalating Medical Costs Dampen Centene's Q2 Earnings? (Zacks)
Jul-22-25 09:00AM	BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET (PR Newswire)
Jul-16-25 12:45PM	Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice (Zacks)
09:55AM	Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet (Zacks)
03:51AM	Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money (Motley Fool)
Jul-14-25 11:34PM	Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks (StockStory)
09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Jul-11-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Jul-10-25 11:26PM	Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside (Insider Monkey)
12:10PM	Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:08AM	BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma (Insider Monkey)
Jul-08-25 09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
Jul-01-25 08:45AM	BioMarin Announces Completion of Acquisition of Inozyme (PR Newswire)
Jun-28-25 04:16AM	BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A (Insider Monkey)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jun-26-25 04:19AM	The Top 5 Analyst Questions From BioMarin Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-25-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-24-25 09:00AM	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress (PR Newswire)
Jun-23-25 01:36AM	Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating (Insider Monkey)
12:01AM	2 Reasons to Watch BMRN and 1 to Stay Cautious (StockStory)
Jun-20-25 05:00PM	Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders (GlobeNewswire)
Jun-15-25 05:26AM	Jim Cramer on BioMarin: "I Don't Think It Works Now" (Insider Monkey)
Jun-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-09-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-05-25 03:06AM	Here Are All 6 Stocks I've Bought Through 5 Months of 2025 (Motley Fool)
May-28-25 11:40AM	Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? (Zacks)
May-26-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks)
09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	May 20 '25	Sale	59.31	1,786	105,928	14,173	May 20 05:58 PM
Burkhart Erin	Officer	May 20 '25	Proposed Sale	59.31	1,786	105,928		May 20 09:58 AM
Hubbard Cristin	EVP, Chief Commercial Officer	May 02 '25	Sale	64.92	273	17,723	32,700	May 06 05:07 PM
Hubbard Cristin	Officer	May 02 '25	Proposed Sale	64.92	273	17,723		May 02 10:05 AM
Burkhart Erin	GVP, Chief Accounting Officer	Mar 19 '25	Sale	71.52	1,295	92,618	16,955	Mar 20 07:38 PM
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Nov 12 '24	Sale	66.37	5,278	350,324	68,909	Nov 14 02:44 PM
Guyer Charles Greg	Officer	Nov 12 '24	Proposed Sale	66.37	5,278	350,324		Nov 12 02:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMRN

Biomarin Pharmaceutical Inc

Upgrade your FINVIZ experience